Clinical Trial Detail

NCT ID NCT04493164
Title CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors M.D. Anderson Cancer Center
Indications

myeloproliferative neoplasm

acute myeloid leukemia

myelodysplastic syndrome

Therapies

CPX-351 + Ivosidenib

Ivosidenib

Age Groups: adult senior

Additional content available in CKB BOOST